Pneumocafé project: An inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education

Multidisciplinary Respiratory Medicine

Volumn 9, Issue 1, 2014, Pages

  Sanguinetti, Claudio M ^a   De Benedetto, Fernando ^b   Donner, Claudio F ^c   Nardini, Stefano ^d   Visconti, Alberto ^e  

^a Consultant in Respiratory Medicine and CEO of FISAR ^*  (Italy)

^b Ospedale di Cento Fe   (Italy)

^c Mondo Medico   (Italy)

^d Pulmonary and TB Unit Vittorio Veneto (TV)   (Italy)

^e FISAR ICT Engineer and Consultant   (Italy)

Author keywords

COPD diagnosis; Early diagnosis; General practice; GPs; Respiratory specialist; Spirometry

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BRONCHUS OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG PREFERENCE; DYSPNEA; EARLY DIAGNOSIS; FEMALE; GENERAL PRACTITIONER; HUMAN; ITALY; LONG TERM CARE; MALE; MEDICAL EDUCATION; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY MEDICAL CARE; PULMONOLOGIST; SCREENING; SMOKING; SPIROMETRY;

EID: 84950270517     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-9-35     Document Type: Article

References (81)

1. Agenzia Nazionale per i Servizi Sanitari Regionali (AGENAS): Broncopneumopatia Cronica Ostruttiva-Linee Guida Nazionali di Riferimento per la Prevenzione e la Terapia. Roma. 2011. Available from: http://www.agenas.it.
2. Bettoncelli G, Blasi F, Brusasco V, Centanni S, Corrado A, De Benedetto F, De Michele F, Di Maria GU, Donner CF, Falcone F, Mereu C, Nardini S, Pasqua F, Polverino M, Rossi A, Sanguinetti CM: The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine). Multidiscip Resp Med 2014, 9:25.
3. GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD: Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available from: http://www.goldcopd.org/.
4. Cause-Specific Mortality, 2008: WHO Region by Country. Geneva: World Health Organization; 2011. http://apps.who.int/gho/data/node.main.887?lang=en.
5. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, et al: Global and regional mortality from 235 causes of death for 20 age groups in1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
6. Murray CJL, Lopez AD: Measuring the global burden of disease. N Engl J Med 2013, 369:448-457.
7. European Respiratory Society: In The European Lung Withe Book. Edited by Gibson GJ, Loddenkemper R, Sibille Y, Lundback B. 2013.
8. Ministero della Salute: Relazione Sullo Stato Sanitario Della Popolazione. 2011.
9. Viegi G, Pedreschi M, Pistelli F, DiPede F, Baldacci S, Carrozzi L, Giuntini C: Prevalence of airways obstruction in a general population. European Respiratory Society vs American Thoracic Society definition. Chest 2000, 117(5Suppl2):339S-345S.
10. Bertella E, Zadra A, Vitacca M, on behalf of General Practitioners Distretto 04 ASL 02 Brescia, Italy: COPD management in primary care: is an educational plan for GPs useful? Multidiscip Resp Med 2013, 8:24.
11. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J: Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 2006, 3:211-218.
12. Lucioni C, Donner CF, De Benedetto F, Lusuardi M, Mazzi S, Paggiaro PL, Sanguinetti CM: I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello studio ICE (Italiancosts for exacerbations in COPD). Pharmacoeconomics-Italian Research Articles 2005, 7:119-134.
13. Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF: Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes). Respir Med 2008, 102:92-101.
14. Van Weel C: Underdiagnosis of asthma and COPD: is the general practitioner to blame? Monaldi Arch Chest Dis 2002, 57:65-68.
15. Van Schayck CP, Chavannes NH: Detection of asthma and chronic obstructive pulmonary disease in primary care. Eur Respir J Suppl 2003, 39:16s-22s.
16. Pauwels RA, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364:613-620.
17. Sutherland ER, Cherniack RM: Management of chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2689-2697.
18. Lusuardi M, Lucioni C, De Benedetto F, Mazzi S, Sanguinetti CM, Donner CF: GOLD severity stratification and risk of hospitalization for COPD exacerbations. Monaldi Arch Chest Dis 2008, 69:164-169.
19. Lyngsø AM, Gottlieb V, Backer V, Nybo B, Østergaard MS, Jørgensen HL, Frolich A: Early detection of COPD in primary care. The Copenhagen COPD Screening Project. COPD 2013, 19:208-215.
20. Fumo e patologie respiratorie: Le carte del rischio per Broncopneumopatia Cronica Ostruttiva e Tumore al polmone. http:// www.iss.it/binary/fumo/cont/carte-del-risk-COPD-e-TaP.pdf.
21. Løkke A, Ulrik CS, Dahl R, Plauborg L, Dollerup J, Kristiansen LC, Cording PH, Dehlendorff C, TOP GOLD study group: Detection of previously undiagnosed cases of COPD in a high-risk population identified in general practice. COPD 2012, 9:458-465.
22. Buffels J, Degryse J, Liistro G: Diagnostic certainty, co-morbidity and medication, in a primary care population with presumed airway obstruction: the DIDASCO2 study. Prim Care Respir J 2009, 18:34-40.
23. 27-28. http://healthsearch.it/documenti/Archivio/Report/VIIReport-2011-2012/VII%20Report%20HS.pdf.
24. Lusuardi M, De Benedetto F, Paggiaro P, Sanguinetti CM, Ferri P, Donner CF: A randomized controlled trial on office spirometry in asthma and COPD in standard general practice. Chest 2006, 129:844-852.
25. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
26. Joo MJ, Sharp LK, Au DH, Lee TA, Fitzgibbon ML: Use of spirometry in the diagnosis of COPD: a qualitative study in primary care. COPD 2013, 10:444-449.
27. Albersa M, Schermera T, Molemab J, Kloeka C, Akkermansa R, Heijdrac Y, Van Weel C: Do family physicians' records fit guideline diagnosed COPD? Fam Pract 2009, 26:81-87.
28. Nardini S, Cicchitto G, De Benedetto F, Donner CF, Polverino M, Sanguinetti CM, Visconti A: Audit sull'appropriatezza nell'assistenza integrata della BPCO. Il progetto "ALT-BPCO". Multidiscip Resp Med 2012, 7(5-6):I-XI.
29. Corrado A, Rossi A: How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012, 106:989-997.
30. Aizpurua F, Latorre A, Ibáñez B, Latorre Garcia K, Vergara I, De Arriba JP, Samper R, López-Picadoa A, Apiñaniz A, Bilbao JL: Variability in the detection and monitoring of chronic patients in primary care according to what is registered in the electronic health record. Fam Pract 2012, 29:696-705.
31. Nardini S, De Benedetto F, Sanguinetti CM, Donner CF: per AIMAR (Associazione Scientifica Interdisciplinare per lo studio delle malattie Respiratorie): Il Progetto "SOS Respiro" of AIMAR. I risultati del primo progetto Italiano globale su COPD ed asma. Multidiscip Resp Med 2007, 2:16-23.
32. Incorvaia C, Riario-Sforza GG: Effect of patient education on adherence to drug treatment for chronic obstructive pulmonary disease. Ann Thorac Med 2011, 6:242-243.
33. Pierson DJ: Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respir Care 2006, 51:277-288.
34. Lucas A, Smmenk F, Smeele I, Brouwer T, Van Schayk O: The validity of diagnostic support of an asthma/COPD service in primary care. Brit J Clin Pract 2007, 57:892-896.
35. Caramori GB, Bettoncelli G, Tosatto R, Arpinelli F, Visonà G, Invernizzi G, Novelletto BF, Papi A, Adcock IM, Ciaccia A: Underuse of spirometry bygeneral practitioners for the diagnosis of COPD in Italy. Monaldi Arch Chest Dis 2006, 63:6-12.
36. Sydney S, Sorel M, Quesemberry CP Jr, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care. Chest 2005, 128:2068-2075.
37. Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. Chest 2005, 128:2640-2646.
38. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E, ECHOS-Lung Function Study Group: Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008, 264:361-369.
39. Sin DD, Mann SF: Why are patients with COPD at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
40. Il diabete in Italia. www.istat.it. Accessed 2014.
41. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L: The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 2014, 43:993-1002.
42. Boulet L-P: Respiratory guidelines implementation in Canada. Can Respir J 2007, 14:329-320.
43. Wong GWK, Miravitlles M, Chisholm A, Krishnan JA: Respiratory guidelines- Which Real world? Ann Am Thorac Soc 2014, 11(suppl.2):S85-S91.
44. Boulet L-P, Hernandez P, Devlin H, Freeman MA, Gupta S: Asthma and chronic obstructive pulmonary disease guideline implementation: lessons learned on recruitment of primary care physicians to a knowledge translation study. Can Respir J 2013, 20:275-280.
45. Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson N: Lost in knowledge translation: time for a map? J Contin Educ Health Prof 2006, 26:13-24.
46. Gupta S, Licskai C, Van Dam A, Boulet L-P: Introducing the Canadian Thoracic Association framework for guideline dissemination and implementation, with concurrent evaluation. Can Respir J 2013, 20:263-264.
47. Straus SE, Tetroe JM, Graham ID: Knowledge translation is the use of knowledge in health care decision making. J Clin Epidemiol 2011, 64:6-10.
48. Davies P, Walker AE, Grimshaw JM: A systematic review of the use of theory in the design of guideline dissemination and implementation strategies and interpretation of the results of rigorous evaluations. Implementation Sci 2010, 5:14.
49. Decramer M, Roussos C: Early detection: introduction. Eur Respir J 2003, 21(suppl.39):1-2.
50. Dompeling E, Van Schayck CP, Van Grunsven PM, Van Herwaarden CL, Akkermans R, Molema J, Folgering H, Van Weel C: Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. Ann Intern Med 1993, 118:770-778.
51. Coultas DB, Mapel D, Gagnon R, Lydick L: The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001, 164:372-377.
52. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC: Chronic Obstructive Pulmonary Disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002, 51:1-16.
53. Mohangoo AD, van der Linden MW, Schellevis FG, Raat H: Prevalence estimates of asthma or COPD from a health interview survey and from general practitioner registration: what's the difference? Eur J Public Health 2005, 16:101-105.
54. Hilleman DE, Dewan N, Malesker M, Friedman M: Pharmacoeconomic evaluation of COPD. Chest 2000, 118:1278-1285.
55. Miravitlles M, de la Roza C, Morera J, Montemayor T, Gobartt E, Martin A, Alvarez-Sala JL: Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med 2006, 100:1973-1980.
56. Poels PJ, Schermer TR, Jacobs A, Akkermans RP, Hartman J, Bottema BJ, Van Weel C: Variation in spirometry utilization between trained general practitioners in practices equipped with a spirometer. Scand J Prim Health Care 2006, 24:81-87.
57. Chavannes N, Schermer T, Akkermans R, Jacobs JE, van de Graaf G, Bollen R, Van Schayck O, Bottema B: Impact of spirometry in GPs' diagnostic differentiation and decision making. Respir Med 2004, 98:1124-1130.
58. Jones RCM, Price D, Ryan D, Sims EJ, Von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S, Kearney M, Holton K, Moger A, Freeman D, Chrisholm A, Bateman ED, on behalf of The Respiratory Effectiveness Group: Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med 2014, 2:267-276.
59. De Godoy I, Tanni SE, Sousa Coelho L, dos Santos e Silva Martin R, Parenti LC, Andrade LM, Godoy I: Smoking cessation program as a tool for the early diagnosis of chronic obstructive pulmonary disease. J Bras Pneumol. 2007, 33:282-286.
60. Dirven JAM, Tange HJ, Muris JWM, Van Haaren KMA, Vink G, Van Schayck OCP: Early detection of COPD in general practice: patient or practice managed? A randomised controlled trial of two strategies in different socioeconomic environments. Prim Care Respir J 2013, 22:331-337.
61. Il fumo in Italia. http://www.iss.it/fumo/index.php?lang=1&id=318&tipo=18.
62. Tønnesen P, Carrozzi L, Fagerstroem KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007, 29:390-417.
63. Emery S, Gilpin EA, Ake C, Farkas AJ, Pierce JP: Characterizing and identifying "hard-core" smokers: implications for further reducing smoking prevalence. Am J Public Health. 2000, 90:387-394.
64. Fiore M, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton CG, Henderson PN, Heyman RB, Koh HK, Kottke TE, Lando HA, Mecklenburg RE, Mermelstein RJ, Mullen PD, Orleans CT, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME: Treating tobacco Use and dependence: 2008 update U.S. Public health service clinical practice guideline executive summary. The 2008 PHS guideline update panel, liaisons, and staff. Respir Care 2008, 53:1217-1222.
65. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965.
66. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G: Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
67. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, Zu Wallack RL, Menjoge SS, Serby CW, Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstuctive pulmonary disease. Eur Respir J 2002, 19:217-224.
68. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
69. Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048.
70. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011, 37:264-272.
71. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gasllego B, Celli BR: Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:1395-1399.
72. Tashkin DP: Future of fixed dose long-acting b2 agonist and antimuscarinic combination therapy in COPD. Lancet Respir Med 2013, 1:6-7.
73. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP: UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009, 374:1171-1178.
74. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D: Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med 2013, 107:223-232.
75. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, Calverley P, Rennard S, Wouters EFM, Wedzicha JA, for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
76. Han MK: Medication adherence in COPD: what have we learned? Thorax 2009, 64:922-923.
77. Corden ZM, Bosley CM, Rees PJ, McLellan CG: Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. Chest 1997, 112:1278-1282.
78. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, on behalf of the TRISTAN Study Group: Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005, 60:301-304.
79. Bourbeau J, Bartlett SJ: Patient adherence in COPD. Thorax. 2008, 63:831-838.
80. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
81. Mularski RA, McBurni MA, Donovan JR, Walker KL, Gillespie SE, Vollmer WM: Inhaled Respiratory Therapeutic Adherence and Factors Associated With Adherence in Chronic Obstructive Pulmonary Disease Patients Within a Comprehensive Healthcare System. American Thoracic Society International Conference; 2011:A2260.